Cephalexin Oral Suspension Recalled for Failed Impurities Specifications
Ascend Laboratories is recalling Cephalexin for Oral Suspension due to an out-of-specification result in impurity testing that identified Cephalexin Glucose Adduct during stability analysis.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The source documents an FDA Class II recall with an out-of-specification impurity finding detected during stability testing. No illnesses, hospitalizations, or injuries are reported, making this a precautionary quality issue without evidence of actual patient harm.
Plain-English summary
Ascend Laboratories, LLC is recalling Cephalexin for Oral Suspension, USP, 125 mg per 5 mL (200 mL bottles) distributed nationwide in the USA. The recall was initiated because an out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity identified was Cephalexin Glucose Adduct.
The affected product is manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, LLC, Parsippany, NJ 07054. Affected lot numbers include: 23142343 (Exp Date 6/30/2025), 23143526 (Exp Date 9/30/2025), 23144036 (Exp Date 10/31/2025), 23144269 (Exp Date 11/30/2025), 24140027 (Exp Date 12/31/2025), and 24144282 (Exp Date 10/31/2026), with NDC 67877-544-68.
Patients who have this medication should consult their healthcare provider or pharmacist about whether to continue use or obtain a replacement. Healthcare providers should contact the recalling firm for additional information.
The recalled product
- Product
- CEPHALEXIN (CEPHALEXIN)
- Brand
- CEPHALEXIN
- Manufacturer
- Ascend Laboratories, LLC
- Category
- Drug — Oral Suspension
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (12)
- Lot #: 23142343
- Exp Date: 6/30/2025
- 23143526
- Exp Date: 9/30/2025
- 23144036
- Exp Date: 10/31/2025
- 23144269
- Exp Date: 11/30/2025
- Lot 24140027
- Exp Date: 12/31/2025
- 24144282
- Exp Date: 10/31/2026
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Ascend Laboratories, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · CEPHALEXIN
- ModerateCephalexin Oral Suspension Recalled for Failed Impurity Specifications
FDA (Drugs) · 2025-06-18
- ModerateCephalexin oral suspension recalled for incorrect label dosage amount
FDA (Drugs) · 2024-06-12
- ModerateCephalexin Oral Suspension Recalled for Incorrect Dosage Label
FDA (Drugs) · 2024-06-12
- LowCephalexin for Oral Suspension Recalled for Back Label Error
FDA (Drugs) · 2024-06-12
- LowCephalexin Oral Suspension Recalled for Incorrect Labeling and Missing Dosage Information
FDA (Drugs) · 2024-06-12
Same manufacturer · Ascend Laboratories, LLC
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- LowDabigatran Etexilate Capsules Recalled Over Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateFDA Recalls Amlodipine and Olmesartan Tablets Over Failed Dissolution Test
FDA (Drugs) · 2026-07-29
- ModerateDabigatran Etexilate Capsules Recalled Over Impurity Test Failure
FDA (Drugs) · 2026-07-29
Same hazard · impurity specification
See all →- ModerateLorazepam injection vials failed the total related compounds impurity specification
FDA (Drugs) · 2025-08-06
- ModerateTeva pitavastatin tablets recalled after failing impurity and degradation specifications
FDA (Drugs) · 2025-07-09
- ModeratePitavastatin tablets recalled after failing impurity and degradation specifications
FDA (Drugs) · 2025-07-09
- ModerateH.E.B Allergy Relief Fexofenadine Tablets Recalled for Failed Impurity Specifications
FDA (Drugs) · 2022-01-12
- ModerateHealth Mart Fexofenadine Tablets Recalled for Failed Impurity Specifications
FDA (Drugs) · 2022-01-12